Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma.
about
The role of autologous and allogeneic hematopoietic stem cell transplantation for Hodgkin lymphomaHigh-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantationNCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell TrAllogeneic hematopoietic cell transplantation: the state of the artThe Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients.Hodgkin's lymphoma therapy: past, present, and future.Relapse of lymphoma after allogeneic hematopoietic cell transplantation: management strategies and outcome.Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor.High-dose cyclophosphamide for graft-versus-host disease prevention.Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients.Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis.Outcomes of allogeneic hematopoietic stem cell transplantation for lymphomas: a single-institution experience.Simplified validated prognostic model for progression-free survival after autologous transplantation for hodgkin lymphoma.HLA-haploidentical stem cell transplantation for hematologic malignancies.Optimal treatment for relapsing patients with Hodgkin lymphoma.Allogeneic transplantation for Hodgkin's lymphoma.Hematopoietic cell transplantation for lymphomas.Unrelated and alternative donor allogeneic stem cell transplant in patients with relapsed or refractory Hodgkin lymphoma: a systematic review.High-dose therapy followed by stem cell transplantation in Hodgkin's lymphoma: past and future.Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!Current role of autologous and allogeneic stem cell transplantation for relapsed and refractory hodgkin lymphoma.Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.Improving outcomes after allogeneic hematopoietic cell transplantation for Hodgkin lymphoma in the brentuximab vedotin eraUmbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of post-transplant lymphoproliferative disease.The role of hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma.Seven-year follow-up of allogeneic transplant using BCNU, etoposide, cytarabine and melphalan chemotherapy in patients with Hodgkin lymphoma after autograft failure: importance of minimal residual disease.Allogeneic haematopoietic stem-cell transplantation with reduced intensity conditioning for advanced stage Hodgkin's lymphoma in Sweden: high incidence of post transplant lymphoproliferative disorder.Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma.A prospective investigation of cell dose in single-unit umbilical cord blood transplantation for adults with high-risk hematologic malignancies.Long-term follow-up of allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma.Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR.Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma.Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
P2860
Q26822480-C97F763F-114B-4602-9D57-EF6649F9B4CDQ33941128-50D90168-692F-4316-AB95-1B301AC31534Q34044024-305A231E-3448-4E58-966B-CED77D64574AQ34145155-DCBEA016-F603-428D-9B31-382B1F7176FFQ34240314-3BAC8433-6E2E-41F5-958C-8A6EDD3BEED4Q34296914-BA75AF31-CA81-4714-9F9F-4D26E3D8D659Q35093521-3F3ED59F-18F6-48B3-9CF9-D3F2DC85498DQ35103536-6648E031-793F-4382-A6C5-F9BF71AE8497Q35108791-9F7F38B2-7EFE-4C7F-9B3C-7426FCF9B241Q35110765-97021386-100E-4C18-9904-030051E79A15Q36166896-81421696-F96E-4ADC-9FF1-908203F42C0AQ37388718-8CA2D480-D9B5-4890-9E7A-849D0FE8502BQ37429226-02972114-E64F-47FB-B349-9C31F8757934Q37530611-8DE0EF76-0D40-4957-9549-CBE2E0AAB471Q37627991-CA0A667B-D199-4094-8CC7-A388D7C8DC2EQ37810094-D6342EA6-7550-414C-A036-9DB57754911CQ37820685-710FEDE6-5E62-4D00-A0B9-271F80BBEEEFQ37942817-5B1B2156-1F7B-4ADB-A93F-4D598428A818Q38105131-56DD8541-0F2E-44E3-9851-5831FD205BC5Q38132819-110CD081-99B3-45B4-B422-3BCBD5CF61DCQ38179975-588AEF3D-5A89-4655-9B13-5EE970511FDFQ38368587-F11FF843-E55F-4BEB-BC96-FC088D74CDFFQ38664909-9672CE59-8B44-497E-8E7D-523FC486443AQ38992200-03F4AE7B-18F8-4D20-93F9-55B2B1D394EBQ41353081-261E7B06-A2BC-42A1-A68B-949A7A39FDE9Q43716206-A278D4D5-F71B-474A-86D7-95407F152026Q44407363-251D774A-5676-4202-B404-B89C707F2A33Q46734531-7AEBE177-9BB4-4521-83A9-CC838E52078AQ47603352-3C235E81-331C-4750-93BE-552406EAF40FQ48134193-ACD98B88-7802-4678-B039-DDFDC728CD95Q48328423-9010EC1A-B70F-4B4D-AC02-76B3A06B27F1Q50051516-64AE9470-43FE-4273-8DB0-AD153D2CA87DQ54686087-05BD2E16-D6FA-48A8-8921-44927F46136DQ56383260-2614423C-698B-4E62-8B23-56E04F904140
P2860
Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Unrelated donor reduced-intens ...... d refractory Hodgkin lymphoma.
@ast
Unrelated donor reduced-intens ...... d refractory Hodgkin lymphoma.
@en
Unrelated donor reduced-intens ...... d refractory Hodgkin lymphoma.
@nl
type
label
Unrelated donor reduced-intens ...... d refractory Hodgkin lymphoma.
@ast
Unrelated donor reduced-intens ...... d refractory Hodgkin lymphoma.
@en
Unrelated donor reduced-intens ...... d refractory Hodgkin lymphoma.
@nl
prefLabel
Unrelated donor reduced-intens ...... d refractory Hodgkin lymphoma.
@ast
Unrelated donor reduced-intens ...... d refractory Hodgkin lymphoma.
@en
Unrelated donor reduced-intens ...... d refractory Hodgkin lymphoma.
@nl
P2093
P2860
P50
P1476
Unrelated donor reduced-intens ...... d refractory Hodgkin lymphoma.
@en
P2093
Brent R Logan
Christopher N Bredeson
César O Freytes
David I Marks
Jeanette Carreras
John Gibson
Koen van Besien
Marcel P Devetten
Paolo Anderlini
Parameswaran N Hari
P2860
P304
P356
10.1016/J.BBMT.2008.11.011
P577
2009-01-01T00:00:00Z